Review Article

Cardiac Implications of COVID-19 in Deceased and Recovered Patients: A Systematic Review

Table 2

Comorbidities of the patients at the time of presentation.

HypertensionCHD or CVDDiabetes mellitusCOPDCKDCVA/stroke

AuthorTotalTotalTotalTotalTotalTotal
SurvivorSurvivorSurvivorSurvivorSurvivorSurvivor
NonsurvivorNonsurvivorNonsurvivorNonsurvivorNonsurvivorNonsurvivor
value value value value value value

Wang et al. [11]26 (24.3)13 (12.1)11 (10.3)3 (2.8)3 (2.8)6 (5.6)
16 (18.2)6 (6.8)6 (6.8)2 (2.3)2 (2.3)3 (3.4)
10 (52.6)7 (36.8)5 (26.3)1 (5.3)1 (5.3)3 (15.8)
0.0010.0020.0240.4470.4470.068

Yang et al. [13]NA5 (10)9 (17)4 (8)NANA
2 (10)2 (10)2 (10)7 (13.5)
3 (9)3 (9)2 (6)7 (22)
NANANANA

Zhou et al. [14]58 (30)15 (8)36 (19)6 (3)2 (1)NA
32 (23)2 (1)19 (14)2 (1)0
26 (48)13 (24)17 (31)4 (7)2 (4)
0.0008<0.00010.00510.0470·024

Si et al. [15]NANANANANANA
30 (65.2)9 (18.4)12 (24.5)1 (2)4 (8.2)1 (2)
6521 (17.4)25 (20.7)10 (8.3)5 (4.1)5 (4.1)
110.70.20.30.7

Shi et al. [16]199 (29.7)60 (8.9)97 (14.5)23 (3.4)28 (4.2)22 (3.3)
162 (26.6)39 (6.4)80 (13.1)21 (3.4)16 (2.6)14 (2.3)
37 (59.7)21 (33.9)17 (27.4)2 (3.2)12 (19.4)8 (12.9)
<0.001<0.0010.0041<0.001<0.001

Fang-fang Chen et al. [17]293 (43)80 (11.7)114 (16.7)15 (2.2)27 (4)33 (4.8)
227 (39.3)55 (9.5)96 (16.6)13 (2.3)20 (3.5)20 (3.5)
66 (63.5)25 (24)18 (17.3)2 (1.9)7 (6.7)13 (12.5)
000.86610.1940

Xie et al. [18]308 (42)93 (12.7)138 (18.8)37 (5)13 (1.8)34 (4.6)
122 (36)38 (11.2)60 (17.8)13 (3.8)5 (1.5)14 (4.1)
186 (47.2)55 (14)78 (19.8)24 (6.1)8 (2)20 (5.1)
0.0020.2650.4690.1640.570.544

Chen et al. [19]93 (34)23 (8)47 (17)18 (7)5 (1)4 (1)
39 (24)7 (4)23 (14)7 (4)1 (1)0
54 (48)16 (14)24 (21)11 (10)4 (4)4 (4)
NANANANANANA

Deng et al. [20]NANANANANANA
18 (15.5)4 (3.4)9 (7.8)3 (2.6)
40 (36.7)13 (11.9)17 (15.6)22 (20.2)
<0.0010.0310.066<0.001

Wang et al. [21]92 (31.4%)21 (7.2%)37 (12.6%)11 (3.8%)11 (3.8%)22 (7.5%)
26 (14.7%)7 (4.0%)14 (7.9%)4 (2.3%)2 (1.1%)3 (1.7%)
66 (56.9%)14 (12.1%)23 (19.8%)7 (6.0%)9 (7.8%)19 (16.3%)
<0.0010.0090.0030.0970.004<0.001

Amit et al. [9]85 (54.5)33 (21.2)62 (39.7)13 (8.3)24 (15.4)NA
2392034
6224421020
<0.000010.030.010.10.003

Alamdari et al. [10]214 (46.6%)185 (40.3%)119 (25.19%)32 (28.8%)99 (21.6%)NA
188 (47.5%)156 (39.4%)95 (24.0%)109 (27.5%)76 (19.2%)
26 (41.3%)29 (46%)24 (38.1%)23 (36.5%)23 (36.5%)
0.3590.3180.0180.1430.002

Stefano Ghio et al. [11]NANANANANANA
166 (60.4%)43 (15.9%)39 (14.4%)16 (5.9%)
102 (84.3%)36 (29.8%)19 (15.7%)22 (18.2%)
<0.0010.0020.74<0.001

Yukun et al. [22]38 (37.6%)21 (20.8%)18 (17.8%)16 (15.8%)NANA
20 (30.3%)10 (15.2%)6 (9.1%)9 (25.7%)
18 (51.4%)11 (31.4%)12 (34.3%)7 (10.6%)
0.0370.0550.0020.048

NA= not applicable.